Equity
€673,541 ▲ 16.0%
DEVA PHARMA has made a profit in every financial year since 2013.
DEVA PHARMA
Overview
Lifetime
13 annual accounts with figures on one time axispeak €159,432 (2023)
€143,510▲ 35.2%
peak €102,411 (2023)
€93,689▲ 44.0%
peak €673,541 (2025)
€673,541▲ 16.0%
€349,353▼ 12.2%
Board1 name since 2021
1 directorMuriel DEBEUCKELAERE
Documentsfilings and deeds
29-06-202632 days before the deadline
2025abbreviated format
Gross margin from €106,144 to €143,510Result from €65,053 to €93,689Dividend €1,000Equity from €580,852 to €673,541Cash from €67,754 to €118,740
Key points
from the 2025 annual accountsTurnover
≈ €220,000 estimated
The abbreviated format states no turnover.
Filings
13 annual accounts since 2013
The last five annual accounts were filed 20 to 32 days before the end of the period.
Financial institution: outside the modelBankruptcy probability: sector outside the model
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal, which does not raise the risk
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
32 days early
2024
30 days early
2023
29 days early
2022
28 days early
2021
20 days early
2020
25 days early
2019
25 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 27 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0847315091
Change of role: Muriel DEBEUCKELAERE, from manager to director
Director discharge: Muriel DEBEUCKELAERE · General meeting of 25-01-2024 · Gazette deed
First establishment
Baron van der Bruggenlaan 12, Wielsbeke
Incorporation
published on 23-07-2012 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DEVA PHARMA Wielsbeke | €1.0m | €143,510 | 65.7% | - |
| TJK INVEST Bredene | €1.1m | €148,303 | 22.6% | - |
| LV VENDO Pittem | €1.2m | €154,641 | 78.4% | - |
| HOLLEVOET INVEST Veurne | €0.9m | €122,329 | 25.3% | - |
| Endeavour Holdings Bruges | €1.0m | €138,744 | 16.0% | - |
| People Of Cameleon Ostend | €1.2m | €135,240 | 21.9% | - |
| OSCAR ALFA Bredene | €1.0m | €128,970 | 66.5% | - |
These companies have the same main activity as DEVA PHARMA: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €935,000 and €1.2m, founded between 2010 and 2013.
Official details
Source: KBO- Status
- Active since 03-07-2012Normal situation
- Activity
- Activities of holding companiesNACE 64210
- Establishment unit
- 2.211.125.3918710 Wielsbeke, since 10-07-2012
- Financial year end
- 31 December
- Peppol
- Reachable since 30-09-2025
Annual accounts 2025
- €93,689▲ 44.0%
- €673,541▲ 16.0%
- €1.0m▲ 4.5%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on DEVA PHARMA
DEVA PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €100,385 in 2013 to €143,510 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 29-06-2026, 32 days before the deadline€673,541
▲ 16.0%
€1.0m
▲ 4.5%
€93,689
▲ 44.0%
65.7%
▲ 6.5 percentage points
13.9%
▲ 2.7 percentage points
9.1%
▲ 2.5 percentage points
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance sheet
balance sheet total €1.0m on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
65.7%
Higher than 64% of 6,708 companies in 2025.
9.1%
Higher than 68% of 6,673 companies in 2025.
DEVA PHARMA
Middle half of the sector
80% of the sector
Abbreviated accounts in financial services (NACE 64)
Net result: middle half · Equity: middle half · Balance sheet total: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||||||||||
20/58 |
1.0m | 980,478 | 1.0m | 980,333 | 962,528 | 986,827 | 943,865 | 911,136 | 908,494 | 919,400 | 920,205 | 953,718 | 940,640 | |
21/28 |
905,321 | 907,197 | 908,248 | 909,980 | 911,711 | 901,155 | 900,144 | 900,444 | 906,223 | 912,002 | 917,781 | 924,227 | 903,525 | |
22/27 |
5,321 | 7,197 | 8,248 | 9,980 | 11,711 | 1,155 | 144 | 444 | 6,223 | 12,002 | 17,781 | 24,227 | 3,525 | |
22 |
4,953 | 6,420 | 7,887 | 9,354 | 10,820 | - | - | - | - | - | - | - | - | |
23 |
- | - | - | - | - | - | - | - | - | - | - | 252 | 503 | |
24 |
368 | 777 | 362 | 626 | 890 | 1,155 | 144 | 444 | 6,223 | 12,002 | 17,781 | 23,975 | 3,022 | |
28 |
900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | |
29/58 |
119,223 | 73,281 | 95,631 | 70,354 | 50,817 | 85,672 | 43,721 | 10,692 | 2,271 | 7,398 | 2,423 | 29,491 | 37,115 | |
40/41 |
- | 5,000 | 10,000 | 14,798 | - | - | 5,163 | - | - | - | 1,584 | 12,100 | - | |
40 |
- | - | 10,000 | 14,798 | - | - | - | - | - | - | 1,584 | 12,100 | - | |
41 |
- | 5,000 | - | - | - | - | 5,163 | - | - | - | - | - | - | |
54/58 |
118,740 | 67,754 | 85,148 | 55,108 | 50,171 | 84,585 | 37,445 | 9,606 | 2,271 | 7,398 | 839 | 17,391 | 37,115 | |
490/1 |
483 | 528 | 483 | 448 | 645 | 1,087 | 1,113 | 1,086 | - | - | - | - | - | |
| Balance sheet: equity and liabilities | ||||||||||||||
10/49 |
1.0m | 980,478 | 1.0m | 980,333 | 962,528 | 986,827 | 943,865 | 911,136 | 908,494 | 919,400 | 920,205 | 953,718 | 940,640 | |
10/15 |
673,541 | 580,852 | 545,895 | 489,334 | 416,330 | 369,904 | 301,203 | 238,663 | 186,167 | 145,929 | 105,986 | 75,588 | 54,202 | |
10/11 |
12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | 12,400 | |
100 |
- | - | - | - | - | - | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | |
101 |
- | - | - | - | - | - | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | 6,200 | |
13 |
660,330 | 567,650 | 532,606 | 476,046 | 403,146 | 356,762 | 288,062 | 225,522 | 173,026 | 133,176 | 93,176 | 62,176 | 41,176 | |
130/1 |
- | - | 1,860 | 1,860 | 1,860 | 1,860 | - | - | - | - | - | - | - | |
130 |
- | - | - | - | - | - | 1,860 | 1,860 | 1,860 | 1,860 | 1,860 | 1,860 | 1,860 | |
1311 |
- | - | 1,860 | 1,860 | 1,860 | 1,860 | - | - | - | - | - | - | - | |
132 |
- | - | - | - | - | 6,316 | 6,316 | 6,316 | 6,316 | 6,316 | 6,316 | 6,316 | 6,316 | |
133 |
660,330 | 567,650 | 530,746 | 474,186 | 401,286 | 348,586 | 279,886 | 217,346 | 164,850 | 125,000 | 85,000 | 54,000 | 33,000 | |
14 |
810 | 802 | 889 | 888 | 784 | 742 | 742 | 742 | 742 | 354 | 411 | 1,012 | 626 | |
16 |
1,650 | 1,650 | 1,650 | 1,650 | 1,630 | 1,600 | 1,600 | 1,600 | 1,590 | 1,560 | 1,530 | 1,500 | 1,500 | |
160/5 |
1,650 | 1,650 | 1,650 | 1,650 | 1,630 | 1,600 | 1,600 | 1,600 | 1,590 | 1,560 | 1,530 | 1,500 | 1,500 | |
164/5 |
1,650 | 1,650 | 1,650 | 1,650 | 1,630 | 1,600 | 1,600 | 1,600 | 1,590 | 1,560 | - | - | - | |
17/49 |
349,353 | 397,976 | 456,334 | 489,349 | 544,568 | 615,323 | 641,061 | 670,873 | 720,737 | 771,911 | 812,688 | 876,630 | 884,938 | |
17 |
33,559 | 77,586 | 120,807 | 163,236 | 205,267 | 244,422 | 282,270 | 318,854 | 357,453 | 397,970 | 443,418 | 493,840 | 515,503 | |
170/4 |
33,559 | 77,586 | 120,807 | 163,236 | 205,267 | 244,422 | 282,270 | 318,854 | 357,453 | 397,970 | 443,418 | 493,840 | 515,503 | |
42/48 |
315,795 | 320,390 | 335,528 | 326,113 | 339,300 | 370,901 | 358,791 | 352,019 | 363,284 | 373,941 | 369,270 | 382,790 | 369,435 | |
42 |
44,027 | 43,221 | 42,429 | 41,652 | 39,155 | 37,848 | 36,584 | 38,599 | 40,517 | 45,448 | 50,422 | 49,188 | 42,342 | |
43 |
- | - | - | - | - | - | 3,624 | - | - | - | 1,007 | - | - | |
430/8 |
- | - | - | - | - | - | 3,624 | - | - | - | 1,007 | - | - | |
44 |
194 | 248 | 195 | 115 | 114 | 523 | 30 | 153 | 71 | 66 | 54 | - | - | |
440/4 |
194 | 248 | 195 | 115 | 114 | 523 | 30 | 153 | 71 | 66 | 54 | - | - | |
45 |
24,655 | 19,295 | 31,617 | 22,349 | 23,264 | 27,843 | 12,852 | 6,242 | 17,046 | 15,598 | 10,719 | 26,736 | 18,464 | |
450/3 |
24,655 | 19,295 | 31,617 | 22,349 | 23,264 | 24,918 | 12,852 | 6,242 | 17,046 | 15,598 | 7,862 | 26,736 | 18,464 | |
454/9 |
- | - | - | - | - | 2,925 | - | - | - | - | 2,856 | - | - | |
47/48 |
246,918 | 257,626 | 261,287 | 261,997 | 276,767 | 304,686 | 305,701 | 307,025 | 305,650 | 312,828 | 307,068 | 306,866 | 308,630 | |
| Income statement | ||||||||||||||
76A |
- | 70 | - | - | - | - | - | - | - | - | 65 | - | - | |
9900 |
143,510 | 106,144 | 159,432 | 126,555 | 84,848 | 111,658 | 106,309 | 101,402 | 91,808 | 85,298 | 74,322 | 61,339 | 100,385 | |
630 |
1,876 | 2,035 | 1,731 | 1,731 | 917 | 380 | 300 | 5,779 | 5,779 | 5,779 | 6,445 | 6,694 | 3,770 | |
635/8 |
- | - | - | 20 | 30 | - | - | 10 | 30 | 30 | 30 | - | 1,500 | |
640/8 |
1,648 | 1,646 | 1,543 | 1,423 | 1,418 | 1,412 | 1,400 | 1,220 | 1,385 | 1,376 | 1,373 | 916 | 98 | |
9901 |
139,987 | 102,464 | 156,157 | 123,381 | 82,483 | 109,866 | 104,609 | 94,392 | 84,614 | 78,113 | 66,474 | 53,729 | 95,017 | |
75/76B |
- | - | - | - | - | - | - | - | - | 0 | 6 | 31 | 40 | |
75 |
- | - | - | - | - | - | - | - | - | 0 | 6 | 31 | 40 | |
65/66B |
8,612 | 12,412 | 12,027 | 16,445 | 11,162 | 10,907 | 13,734 | 17,019 | 17,980 | 18,659 | 21,140 | 21,453 | 36,536 | |
65 |
8,612 | 12,412 | 12,027 | 16,445 | 11,162 | 10,907 | 13,734 | 17,019 | 17,980 | 18,659 | 21,140 | 21,453 | 36,536 | |
9903 |
131,375 | 90,052 | 144,130 | 106,936 | 71,321 | 98,958 | 90,875 | 77,374 | 66,633 | 59,454 | 45,405 | 32,307 | 58,521 | |
67/77 |
37,686 | 24,999 | 41,720 | 29,932 | 20,895 | 27,258 | 25,334 | 21,878 | 24,783 | 17,899 | 13,394 | 9,310 | 15,107 | |
9904 |
93,689 | 65,053 | 102,411 | 77,004 | 50,426 | 71,701 | 65,540 | 55,496 | 41,850 | 41,555 | 32,010 | 22,998 | 43,414 | |
789 |
- | - | - | - | 6,316 | - | - | - | - | - | - | - | - | |
689 |
- | - | - | - | - | - | - | - | - | - | - | - | 6,316 | |
9905 |
93,689 | 65,053 | 102,411 | 77,004 | 56,741 | 71,701 | 65,540 | 55,496 | 41,850 | 41,555 | 32,010 | 22,998 | 37,098 | |
| Appropriation of the result | ||||||||||||||
9906 |
94,490 | 65,942 | 103,299 | 77,788 | 57,484 | 72,442 | 66,282 | 56,237 | 42,204 | 41,966 | 33,023 | 23,624 | 37,098 | |
14P |
802 | 889 | 888 | 784 | 742 | - | - | - | - | - | - | - | - | |
791/2 |
1,000 | 29,956 | 45,850 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 2,000 | - | - | - | - | |
691/2 |
93,680 | 65,000 | 102,410 | 76,900 | 56,700 | 71,700 | 65,540 | 55,496 | 41,850 | 40,000 | 31,000 | 21,000 | 34,860 | |
6920 |
- | - | - | - | - | - | - | - | - | - | - | - | 1,860 | |
6921 |
93,680 | 65,000 | 102,410 | 76,900 | 56,700 | 71,700 | 65,540 | 55,496 | 41,850 | 40,000 | 31,000 | 21,000 | 33,000 | |
694/7 |
1,000 | 30,096 | 45,850 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 1,612 | 1,612 | 1,612 | 1,612 | 1,612 | |
694 |
1,000 | 30,096 | 45,850 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 1,612 | 1,612 | 1,612 | 1,612 | 1,612 | |
| Document | ||||||||||||||
The notes to these accounts have 8 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 29-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 29-06-2026 | 2026-00211271 | |
| 31-12-2024 | abbreviated format | 01-07-2025 | 2025-00207459 | |
| 31-12-2023 | abbreviated format | 02-07-2024 | 2024-00195462 | |
| 31-12-2022 | abbreviated format | 03-07-2023 | 2023-00197599 | |
| 31-12-2021 | abbreviated format | 11-07-2022 | 2022-20175204 | |
| 31-12-2020 | abbreviated format | 06-07-2021 | 2021-32000214 | |
| 31-12-2019 | abbreviated format | 06-07-2020 | 2020-26800386 | |
| 31-12-2018 | abbreviated format | 23-07-2019 | 2019-36900140 | |
| 31-12-2017 | abbreviated format | 18-07-2018 | 2018-34700518 | |
| 31-12-2016 | abbreviated format | 03-07-2017 | 2017-26300512 | |
| 31-12-2015 | abbreviated format | 19-07-2016 | 2016-32900139 | |
| 31-12-2014 | abbreviated format | 23-07-2015 | 2015-33400117 | |
| 31-12-2013 | abbreviated format | 28-08-2014 | 2014-49500144 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 983 | 0 | 0 | 11,473 | 1,391 | 0 | 0 | 0 | 0 | 0 | 27,396 | 906,316 | ||
| 50,987 | -17,394 | 30,040 | 4,936 | -34,414 | 47,140 | 27,839 | 7,335 | -5,126 | 6,558 | -16,552 | -19,724 | - | ||
| 65.7% | 59.2% | 54.4% | 49.9% | 43.3% | 37.5% | 31.9% | 26.2% | 20.5% | 15.9% | 11.5% | 7.9% | 5.8% | ||
| 13.9% | 11.2% | 18.8% | 15.7% | 12.1% | 19.4% | 21.8% | 23.3% | 22.5% | 28.5% | 30.2% | 30.4% | 80.1% | ||
| 9.1% | 6.6% | 10.2% | 7.9% | 5.2% | 7.3% | 6.9% | 6.1% | 4.6% | 4.5% | 3.5% | 2.4% | 4.6% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | €983 | - | - | €11,473 |
| €1,876 | €2,035 | €1,731 | €1,731 | €917 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on DEVA PHARMA
The operating result for 2025 is 37% higher than in 2024. It is a recovery after the fall in 2024.
Debt's share of the balance-sheet total falls from 40.6% to 34.1%. Equity is higher and debt is lower.
Board & ownership
Board
1 director, last change in 2024Director (not named in the articles)
appointed by deed of 12-02-2024
term without a fixed end
earlier manager, until 12-02-2024
listed in the 2025 annual accounts, filed on 29-06-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Iedere bestuurder vertegenwoordigt de vennootschap jegens derden en in rechte als eiser of als verweerder. Hij kan bijzondere machten…”deed of 12-02-2024
Mandates through the years
1 name, the dashed line is todayMuriel DEBEUCKELAERE
Director (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
- Muriel DEBEUCKELAERE
- Director (not named in the articles), since before 31-12-2021
- Manager, until 12-02-2024
Control
Capital
- Contribution
- €12,400
- Source
- 2025 annual accounts
Articles of association
deed of 12-02-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Meerderheid aanwezig, alle_handelingen_nodig_of_nuttig_voor_voorwerp_behalve_wet_of_statuten_aan_AV”
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Helft overdrager,helft kopers naar evenredigheid van verworven aandelen, instemming van alle aandeelhouders op straffe van nietigheid”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of June at 14:00
Network & group
Holdings
own 2025 accountsThis companyDEVA PHARMA1 holding, 1 country
2025 accounts
Belgium 1 Equity Result
- BE BV APOTHEEK DEBEUCKELAERE €400,717 result €48,940
Source: list of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.
At the same address
Ridder de Ghellinckstraat 28, 8710 Wielsbeke · 1 other company| Vanoutryve, Kenny (sole trader)
establishment since 01-04-2008 |
founded in 2008 0896.689.972 |
Holdings and subsidiaries
1 holdingHoldings 1
Share, source and own figures per holding (1)
- APOTHEEK DEBEUCKELAEREsubsidiaryEquity €400,717 Profit of €48,940 in 2025 (profit of €53,382 in 2024) Checked score 96Sourceown accounts 2025100%
Holdings through the years 2013 to 2025
| Name | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APOTHEEK DEBEUCKELAERE | 100% | ||||||||||||
Source: list of holdings in its own accounts
Board mandates elsewhere
1 board mandateBoard mandates of DEVA PHARMADEVA PHARMA sits on their board1
Connections & network
1 current directorThe board mandates are listed under Board mandates elsewhere. The network lets you explore the same ties.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Timeline
23 events since 2012Board
Filings
Financial
Establishments
20122014201620182020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 32 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0847315091
Annual accounts 2024 filed PDFabbreviated format · 30 days before the deadline
2024
Annual accounts 2023 filed PDFabbreviated format · 29 days before the deadline
Change of role: Muriel DEBEUCKELAERE, from manager to directorDirector discharge: Muriel DEBEUCKELAERE · General meeting of 25-01-20246 points ▸
- General meeting, 25-01-2024
- Registered office clause, Ridder de Ghellinckstraat 28, 8710 Wielsbeke
- Director resignation, Muriel DEBEUCKELAERE (manager)
- Director appointment, Muriel DEBEUCKELAERE (director (not named in the articles))
- Director discharge, Muriel DEBEUCKELAERE
- 186 shares
- The deed holds 5 more points.
2023
Highest result from 2013 to 2025 net €102,411 ▲33% The operating result of €156,157 and the net result of €102,411 are both a record.
Equity above €500,000 equity €545,895 ▲11.6% With a profit in every financial year since 2013, equity grows to €545,895.
Annual accounts 2022 filed PDFabbreviated format · 28 days before the deadline
2022
Annual accounts 2021 filed PDFabbreviated format · 20 days before the deadline
2021
Annual accounts 2020 filed PDFabbreviated format · 25 days before the deadline
2020
Annual accounts 2019 filed PDFabbreviated format · 25 days before the deadline
2019
Annual accounts 2018 filed PDFabbreviated format · 8 days before the deadline
2018
Equity above €200,000 equity €238,663 ▲28.2% With a profit in every financial year since 2013, equity grows to €238,663.
Annual accounts 2017 filed PDFabbreviated format · 13 days before the deadline
2017
Equity above €150,000 equity €186,167 ▲27.6% With a profit in every financial year since 2013, equity grows to €186,167.
Annual accounts 2016 filed PDFabbreviated format · 28 days before the deadline
2016
Annual accounts 2015 filed PDFabbreviated format · 12 days before the deadline
2015
Equity above €100,000 equity €105,986 ▲40.2% With a profit in every financial year since 2013, equity grows to €105,986.
Annual accounts 2014 filed PDFabbreviated format · 8 days before the deadline
2014
Weakest financial year net €22,998 ▼47% The net result drops to €22,998, the lowest from 2013 to 2025. It recovers the following year.
Annual accounts 2013 filed PDFabbreviated format · 28 days late
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0847.315.091
- VAT number
- BE 0847.315.091
- Peppol ID
- 0208:0847315091
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 03-07-2012
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of June at 14:00deed of 12-02-2024 (in Dutch)
- Peppol
- Reachable since 30-09-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- DEVA PHARMA in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 12-02-2024 (in Dutch)
- Name clauseThe company operates under this name according to its articles.
- Deva Pharmadeed of 12-02-2024 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 12-02-2024 (in Dutch)
Activities
NACEBEL 202564210
Activities of holding companies main activity
Codes under NACEBEL 2008
64200
Holdings main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Het verlenen van diensten en adviezen aan derden; Het verwerven van participaties,in eender welke vorm,in alle bestaande of op te richten…”deed of 12-02-2024 (in Dutch)
8 activities
- Het verlenen van diensten en adviezen aan derden.
- Het verwerven van participaties,in eender welke vorm,in alle bestaande of op te richten rechtspersonen of ondernemingen;het stimuleren,plannen en coördineren van de ontwikkeling van voormelde rechtspersonen of ondernemingen.
- Het waarnemen van bestuursopdrachten en –mandaten,het uitoefenen van opdrachten en functies.
- Het onderzoek,de ontwikkeling,de vervaardiging of commercialisering van nieuwe producten en technologieën en hun toepassingen;het ontwikkelen,kopen,verkopen,in licentie nemen of geven van octrooien,knowhow en aanverwante immateriële vaste activa;
- De aan- en verkoop,evenals de in- en uitvoer van om het even welke goederen.
- Het aanleggen,het oordeelkundig uitbouwen en beheren van een onroerend vermogen;alle verrichtingen met betrekking tot onroerende goederen en onroerende zakelijke rechten(vruchtgebruik,recht van opstal,erfpacht,…),zoals de huurfinanciering van onroerend goederen aan derden,het aankopen,verkopen,ruilen,bouwen,verbouwen,onderhouden,verhuren,huren,verkavelen,prospecteren en uitbaten van onroerende goederen,het ontwerpen en opvolgen van projecten,en het maken van studies met betrekking tot immobiliën;de aan- en verkoop,huur en verhuur van roerende goederen betreffende de inrichting en uitrusting van onroerende goederen,alsmede alle handelingen die rechtstreeks of onrechtstreeks met dit voorwerp in verband staan en die van aard zijn de opbrengst van de onroerende goederen te bevorderen;alsmede zich borg stellen voor het goede verloop van verbintenissen,door derde personen aangegaan,die het genot zouden hebben van voormelde roerende en onroerende goederen.
- Het aanleggen,het oordeelkundig uitbouwen en beheren van een roerend vermogen;alle verrichtingen met betrekking tot roerende goederen en rechten,van welke aard ook,zoals het verwerven door inschrijving of aankoop,het beheren van aandelen,aandelenopties,obligaties,kasbons,afgeleide producten of andere roerende waarden,van welke vorm ook,uitgegeven door Belgische of buitenlandse emittenten.
- Het toestaan van leningen en kredietopeningen aan rechtspersonen en ondernemingen of particulieren,in eender welke vorm;het zich borg stellen of aval verlenen,het verlenen van zakelijke borgen op haar activa,in de meest ruime zin;alle handelsoperaties en financiële operaties verrichten,behalve deze die wettelijk voorbehouden zijn aan depositobanken,houders van deposito’s op korte termijn,spaarkassen,hypotheekmaatschappijen en kapitalisatieondernemingen.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Ridder de Ghellinckstraat 28 registered office 8710 Wielsbeke | ||
| Baron van der Bruggenlaan 12 8710 Wielsbeke | 10-07-2012 | 2.211.125.391 |
Buildings and parcels at the addresses
- Ground area
- 2,754 m²
- Buildings
- 192 m²
- Volume, LiDAR
- 1,117 m³
- Tallest building
- 9.5 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 37017A0423/00G000 | 1,473 m² | 1 · 176 m² | 9.5 m · 2 |
| 37017C0151/00H014 | 1,281 m² | 1 · 16 m² | 1.9 m · 1 |